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Introduction
Deregulation of gene expression can cause devastating cancers. 
Fusion of the mixed-lineage leukemia (MLL) gene (also known 
as KMT2A, MLL1, ALL-1, or HTRX) and various partners caus-
es aggressive leukemia (1). The resultant MLL fusion proteins 
constitutively activate their target genes, such as homeobox A9 
(HOXA9) and Meis homeobox 1 (MEIS1), whose expression levels 
are elevated in the hematopoietic stem cell/multipotent progen-
itor fractions and are progressively suppressed during differen-
tiation (2, 3). MLL fusion proteins form a complex with MENIN 
and lens epithelium–derived growth factor (LEDGF, also known 
as PSIP1) to recognize their target genes (4, 5) by binding di- or 
trimethylated histone H3 lysine 36 (H3K36me2/3) through the 
PWWP domain of LEDGF and nonmethylated CpGs through the 
CXXC domain of MLL (6–9). Consequently, the target chromatin 
of MLL is mostly located at the promoter proximal region, where 
CpGs are enriched (6).
To date, more than 70 genes have been reported to fuse with 
MLL (10). Despite its promiscuity, the majority of MLL-rearranged 
leukemia (MLL-r leukemia) cases are caused by MLL fusion with a 
component of either the AF4–ENL–P-TEFb (AEP) complex or the 
DOT1L-AF10-ENL complex (referred to as the DOT1L complex) 
(11–16). These 2 complexes include a member of the ENL family 
such as eleven-nineteen leukemia (ENL, also known as MLLT1) 
and AF9 (also known as MLLT3). The ENL family proteins contain 
a YEATS domain, which recognizes acetylated histone H3 lysine 9, 
18, or 27 (H3K9/18/27ac) (17). AEP also contains AF4 family pro-
teins, including AF4 (also known as AFF1) and AF5Q31 (also known 
as AFF4), which provide various interaction platforms for cofactors 
(11, 14–16). The AF4 family proteins associate with the phosphor-
ylated transcription elongation factor b (P-TEFb) complex and the 
ELL protein family, both of which demonstrate transcription elon-
gation activities (18, 19). Additionally, AF4 family proteins associate 
with selectivity factor 1 (SL1), containing TATA box–binding protein 
(TBP) and TBP-associated factor RNA polymerase I subunits A 
through D (TAF1A/B/C/D), to initiate RNA polymerase II–depen-
dent (RNAP2-dependent) transcription, which is the critical step 
activated by MLL-AEP fusion proteins in leukemic transformation 
(20, 21). Thus, AEP is a multifunctional coactivator that can facili-
tate both the initiation and elongation of transcription.
DOT1L is an epigenetic modifier that produces mono-, di-, 
and trimethylated histone H3 lysine 79 (H3K79me1/2/3) (22, 
23) and maintains a protective chromatin environment against 
sirtuin 1–dependent (SIRT1-dependent) gene silencing (24). The 
DOT1L complex is mainly composed of DOT1L, an ENL family 
protein, and an AF10 family protein, such as AF10 (also known as 
MLLT10) or AF17 (also known as MLLT6) (13). The association of 
DOT1L with AF10 increases the histone methyltransferase (HMT) 
activity of DOT1L to produce highly methylated H3K79me2/3 
markers (25), and their presence, in turn, correlates with active 
transcription. MLL-AF10 transforms hematopoietic progenitors 
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observed at known AEP target genes such as HOXA9 (11) (Sup-
plemental Figure 1C), which was confirmed by a more sensitive 
ChIP–quantitative PCR (ChIP-qPCR) analysis (Supplemental 
Figure 1D). The distribution pattern of ENL relative to the tran-
scriptional start sites (TSSs) indicated that ENL was enriched 
within the promoter proximal coding region 0 to +2 kb from the 
TSSs, colocalizing with H3K9/27ac (Figure 1F). Components of 
AEP, SL1, and the DOT1L complex were also enriched at the pro-
moter proximal coding region. In contrast, BMI1 and CBX8 were 
not specifically localized to these ENL target genes, which were 
actively transcribed, as indicated by the ChIP signal of RNAP2 and 
the RNA-seq profile (Figure 1, E and F, and Supplemental Figure 
1, C and D). Taken together, AEP and the DOT1L complex act at 
the promoter proximal region where PRC1 is absent, suggesting 
that AEP and the DOT1L complex may cooperate to activate gene 
expression in the absence of PRC1.
DOT1L is required for AEP-SL1 complex–dependent gene acti-
vation. Given the proximity of the localization of AEP and the 
DOT1L complex, we hypothesized that DOT1L plays an active role 
in AEP-dependent transcriptional activation. To examine the role 
of DOT1L in the expression of AEP-SL1 target genes, we knocked 
down Dot1l in immortalized mouse embryonic fibroblasts (iMEFs) 
using shRNA. The expression of homeobox C8 (Hoxc8), homeobox 
C9 (Hoxc9), and cyclin-dependent kinase inhibitor 2C (Cdkn2c) 
depends on Enl and Taf1c in iMEFs (Figure 2A) (20). Knockdown 
of Dot1l with 2 different shRNAs decreased the expression of these 
AEP-SL1 target genes. RNA-seq analysis showed that Dot1l knock-
down globally reduced the expression of the AEP-SL1 target gene 
set (Figure 2B), which was defined as the genes commonly down-
regulated by knockdown of Enl and Taf1c (Supplemental Figure 
2A). These results indicate that the DOT1L complex is required for 
efficient AEP-SL1–dependent gene activation under non–MLL-r 
conditions. Such cooperative gene activation was also observed 
in a hematopoietic context, as AEP-SL1 components colocalized 
with the DOT1L complex at the MYC locus in K562 leukemia cells 
(Supplemental Figure 2B), and knockdown of each component 
resulted in a decrease in MYC expression (Supplemental Figure 
2C). These results suggest that AEP-DOT1L collaboration is com-
mon among various cellular contexts.
The MLL-ENL–AEP hybrid complex, the DOT1L complex, and 
PRC1 differentially localize on chromatin. To determine the roles 
of AEP, the DOT1L complex, and PRC1 in MLL-ENL–depen-
dent gene activation in leukemia cells, we analyzed the genom-
ic localization of each component in HB1119 leukemia cells, 
which endogenously express both MLL-ENL and WT MLL (40). 
ChIP-seq analysis using 2 different antibodies showed that MLL 
proteins localized mainly to the region –1 to +2 kb from the TSS 
(Figure 3, A and B, and Supplemental Figure 3A), a finding that 
was supported by ChIP-qPCR analysis on select loci (Supplemen-
tal Figure 3B). Since near-complete knockdown of WT MLL by 
shRNA did not compromise the expression of HOXA9 or MEIS1 or 
the recruitment of MLL proteins and MLL-ENL–specific cofactors 
(Supplemental Figure 3, C–F), the ChIP signal of MLL proteins can 
be attributed mostly to MLL-ENL.
Distribution patterns of AF4 and TAF1C were nearly identical 
to that of MLL-ENL (Figure 3, A and B). The ChIP signal intensity 
of MLL-ENL was highly correlated with that of AF4 (r = 0.8398) 
through the DOT1L interaction domain (26), while MLL-ENL/
AF9 does so through the ANC1 homology domain (AHD), which 
is responsible for its association with both AF4 and DOT1L (11, 
12, 27). Genetic ablation of Dot1l results in the loss of clonogenic 
activity of MLL-AF10– and MLL-AF9–transformed hematopoietic 
progenitors, indicating that the presence of DOT1L is required for 
MLL fusion–dependent leukemic transformation (28–32). Selec-
tive inhibitors of DOT1L HMT that show efficacy against MLL-r 
leukemia have been developed (33, 34). Paradoxically, ENL family 
proteins associate with polycomb-repressive complex 1 (PRC1), 
which is known to suppress transcription (12). Upon double-strand 
breaks, ATM (ataxia telangiectasia mutated) phosphorylates the 
ENL family protein to switch its binding partner from the AF4 
family protein to PRC1 to suppress transcription (35). However, 
the interrelationship among AEP, the DOT1L complex, and PRC1 
and its implications in MLL fusion–dependent leukemogenesis 
are largely unclear.
In this study, we investigated the mechanisms of gene regula-
tion by the 3 ENL-containing complexes and identified 2 essential 
transcriptional properties that are overactivated by MLL-ENL and 
MLL-AF10 in leukemogenesis, both of which should be simulta-
neously targeted to efficiently eradicate MLL stem cells.
Results
ENL colocalizes with components of the AEP and DOT1L complexes 
in the promoter proximal coding regions. To dissect the biochemical 
properties of ENL bound to chromatin, we performed immuno-
affinity purification from subcellular fractions containing nucle-
osomes (nucleosome fraction immunoprecipitation [nucfrIP]) 
(6) (Figure 1A and Supplemental Figure 1, A and B; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI91406DS1). Consistent with a previous report (12), we found 
that ENL associated with components of AEP (e.g., AF5Q31 and 
cyclin T1), the DOT1L complex (e.g., DOT1L and AF17), and PRC1 
(e.g., chromobox 2 [CBX2] and BMI1 proto-oncogene, polycomb 
ring finger [BMI1]) via its AHD, as shown by the failure of an 
AHD-lacking ENL mutant to coprecipitate with these cofactors. A 
similar coprecipitation analysis in more stringent conditions (frac-
tionation-assisted native ChIP [fanChIP]), followed by Western 
blotting (WB) (6), showed that MLL-ENL associated with these 
components of the AEP, DOT1L, or PRC1 complexes (Figure 1B). 
ENL interacts with the 3 distinct complexes in a mutually exclusive 
manner (11, 36–38). Thus, exogenously expressed CBX8, a PRC1 
component, pulled down ENL and BMI1, but not AEP- or DOT1L 
complex–specific components (Figure 1C). Mass spectrometric 
(MS) analysis of the nucleosomes copurified with ENL showed 
enrichment of both unmodified and acetylated lysine 27 on histone 
H3 (unmodified H3K27 and H3K27ac, respectively) (Figure 1D), 
consistent with the model demonstrating that the YEATS domain 
of ENL specifically associates with H3K27ac (17) and the PZP 
domain of AF10 family proteins binds to unmodified H3K27 (39).
To examine the genomic localization of these 3 complexes, 
we used 293T cells to perform ChIP, followed by deep sequenc-
ing (ChIP-seq). The ChIP signals of ENL, AF4, TAF1C, DOT1L, 
and AF17 were highly enriched at ENL target genes such as ribo-
somal protein L13a (RPL13A) and sorting nexin 5 (SNX5) (Figure 
1E). These AEP, SL1, and DOT1L complex components were also 
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Figure 1. Genomic localization of 3 ENL-containing complexes. (A) ENL-associating factors on nucleosomes. 293T cells transiently expressing Xpress-
tagged ENL (xENL) or its AHD-lacking mutant (ΔAHD) were analyzed by nucfrIP copurification using an anti-Xpress antibody. The sample shown in the 
input lane is indicated by an asterisk. (B) Cofactor binding of MLL-ENL. 293T cells transiently expressing FLAG-tagged MLL-ENL were analyzed by fanChIP 
copurification using an anti-FLAG antibody. (C) CBX8-associating factors on nucleosomes. 293T cells transiently expressing Xpress-tagged ENL, with or 
without FLAG-tagged CBX8, were analyzed by nucfrIP copurification using an anti-FLAG antibody. (D) Histone H3K27 modification of the nucleosomes 
coprecipitated with ENL. Purified nucleosomes, as in A, were subjected to MS analysis. The ratio of each modification identified by MS on histone H3K27 
is shown in pie charts. The n values shown indicate the number of peptides analyzed. ac, acetylated. (E) Genomic localization of ENL-containing complex-
es and various histone modifications in 293T cells. fanChIP or faxChIP (for H3K79me2), followed by deep sequencing, was performed on the chromatin 
of 293T cells for the indicated proteins and modifications. ChIP signals were visualized using the Integrative Genomics Viewer (The Broad Institute). The 
minimum value of the y axis is set at 0, while the maximum value for each sample is indicated. The RNA-seq profile is also shown for comparison. CGI, CpG 
island; FOXL2, forkhead box L2; MGME1, mitochondrial genome maintenance exonuclease 1. (F) Distribution patterns of various proteins and modifications 
at the ENL target loci. A set of genes (852 genes) whose ENL ChIP signal within the region 0 to +2 kb from the TSS was more than 2-fold of the input signal 
was defined as the representative ENL target set. The frequency of each protein and modification at the ENL target TSSs (black lines) or all TSSs (gray 
lines) is shown along with the input DNA (dashed lines). The y axis indicates the frequency of the ChIP-seq tag count (ppm) in 25-bp increments.
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and insulin-like growth factor 1 receptor (IGF1R). Distribution pat-
terns of BMI1 and CBX8 were skewed toward upstream noncod-
ing regions. Most of the MLL target genes that were enriched with 
BMI1 and CBX8 were genes with relatively low levels of MLL-ENL, 
AF4, and DOT1L localization (Figure 3C and Supplemental Figure 
3G). These results indicate that MLL-ENL primarily forms a MLL-
ENL–AEP hybrid complex at the target promoter in the absence of 
PRC1 and frequently coexists with DOT1L in its proximal coding 
region, while PRC1 colocalizes with MLL-ENL at the upstream 
noncoding region of a subset of MLL target genes, where AEP and 
DOT1L complexes are scarce.
DOT1L recruitment to the MLL target loci delays gene silencing. 
AF10 associates with DOT1L through the octapeptide motif and 
leucine zipper domain (OM-LZ) (26), and AF5Q31 associates with 
AF4 through the carboxyl-terminal homology domain (CHD), 
while ENL binds to both DOT1L and AF4 via AHD (Figure 4A) 
(11). To determine the role of each cofactor in transcriptional 
activation, we generated GAL4 fusion constructs for each bind-
ing platform and performed a transactivation assay using 293TL 
cells (20), in which the galactose-responsive transcription factor 
GAL4–responsive (GAL4-responsive) reporter was integrated 
into the genome. The GAL4-AHD fusion protein (GAL4-ENL′) 
exhibited substantial transactivation activity (~13-fold increase), 
while the GAL4-CHD fusion protein (GAL4-AF5-4) showed 
and TAF1C (r = 0.8689) (Figure 3C and Supplemental Figure 3G), 
suggesting that AEP and SL1 are tethered to chromatin by MLL-
ENL. The distribution patterns of DOT1L and AF17 were similar 
to those of AF4 and TAF1C, but skewed toward coding regions 
(Figure 3B). Moreover, the ChIP signal of DOT1L complex compo-
nents was not in proportion to that of MLL-ENL at some loci (Fig-
ure 3A, NR3C1 and BCL7A). Consequently, localization of DOT1L 
(r = 0.7096) and AF17 (r = 0.7154) was loosely correlated with that 
of MLL-ENL, compared with localization of AEP-SL1 components 
(Figure 3C and Supplemental Figure 3G). These results indicate 
that MLL-ENL primarily associates with AEP components on 
chromatin, while chromatin association with the DOT1L complex 
is partly dependent on the chromatin context in addition to the 
presence of MLL-ENL.
Most of the MLL target chromatin retains a profile of transcrip-
tionally active chromatin with the ChIP signals of di- or trimeth-
ylated histone H3 lysine 4 (H3K4me2/3), H3K27ac, H3K79me2, 
and RNAP2 (Figure 3, A and B and Supplemental Figure 3, A and 
B). Trimethylated histone H3 lysine 27 (H3K27me3) was depleted 
from the MLL target chromatin, with the exception of the HOXA9 
locus, which may be heterochromatinized in a monoallelic man-
ner. BMI1 and CBX8 were absent from most of the MLL target 
promoters, though they were present in a subset of MLL target loci 
such as fat storage–inducing transmembrane protein 2 (FITM2) 
Figure 2. Role of DOT1L in AEP-dependent gene activation. (A) RT-qPCR analysis 
of AEP-SL1 target genes after knockdown of Dot1l in iMEFs. Data for Enl or Taf1c 
knockdown are included for comparison. Expression levels normalized to Actb (rep-
resentative of 2 independent experiments) are shown as the value relative to that 
of the vector control (set at 100%). Error bars represent the SD of PCRs performed 
in triplicate. #P ≤ 0.0001, by unpaired, 2-tailed t test (for sh-Enl or Taf1c) or ordinary 
1-way ANOVA (for sh-Dot1l) comparing each sample with the vector control. puro, 
puromycin. (B) RNA-seq analysis after knockdown of Dot1l in iMEFs. The AEP-SL1 
target gene set was defined as the genes whose expression levels were reduced 
by more than 3-fold by shRNAs for both Enl and Taf1c. GSEA and scatter plots are 
shown. AEP-SL1 target genes are highlighted in blue. The normalized enrichment 
score (NES) and FDR are indicated.
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Figure 3. Genomic landscape of MLL-ENL target chromatin. (A) Genomic localization of various proteins/modifications in HB1119 cells. fanChIP or faxChIP 
(for H3K79me2 and H3K27me3), followed by deep sequencing, was performed on the chromatin of HB1119 cells by using specific antibodies against the 
indicated proteins. ChIP-seq data for RNAP2 were redundant with a previously published data set (20). RNA-seq profile is included for comparison. BCL7A, 
BCL tumor-suppressor 7A; MYB, MYB proto-oncogene, transcription factor; NR3C1, nuclear receptor subfamily 3 group C member 1. (B) Distribution pat-
terns of various proteins/modifications at the MLL target loci. The distribution pattern relative to the TSS was analyzed as described in Figure 1F. A set of 
genes (8,830 genes) whose MLL ChIP signal within the region 0 to +2 kb from the TSSs was greater than 3-fold that of the input was defined as the repre-
sentative MLL target set. (C) Relative occupation of various factors at MLL target genes. ChIP-seq tags of the MLL target set were clustered into a 2-kb bin 
(either 0 to +2 kb from the TSS or –2 to 0 kb, denoted as “(–)”) and are presented as XY scatter plots. Spearman’s rank correlation coefficient (r) is shown.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1 9 2 3jci.org   Volume 127   Number 5   May 2017
Figure 4. DOT1L delays gene silencing induced by differentiation. (A) Transactivation activities of various binding platforms. Schematic structures of 
various FLAG-tagged GAL4 fusion proteins are shown. Transactivation activity normalized to Renilla luciferase activity is shown (error bars represent the 
SD of triplicate experiments) as the value relative to that of GAL4 (set at 1). Black flag denotes the FLAG epitope. NHD, N-terminal–conserved domain; 
ALF, AF4-LAF4-FMR2 homology domain; pSER, poly-serine; A9ID, AF9 interaction domain; MISD, minimum interaction site of DOT1L. (B) Association 
of AF4 and DOT1L with various binding platforms. FLAG-tagged GAL4 fusion proteins were coexpressed with Xpress-tagged AF4 and HA-tagged DOT1L 
and analyzed by fanChIP-WB using an anti-FLAG antibody. Coprecipitated proteins were visualized using specific antibodies against the indicated 
tags. FPs, fusion proteins. (C) Recruitment of cofactors by various binding platforms. Each FLAG-tagged GAL4 fusion protein was expressed in 293TL 
cells and analyzed by ChIP-qPCR using the indicated antibodies and probes specific for the pre-TSS, TSS, and post-TSS regions of the GAL4-responsive 
luciferase reporter. ChIP signals are expressed as the percentage of input. Error bars represent the SD of PCRs performed in triplicate. UAS, upstream 
activation sequence; LUC, Luciferase reporter gene; TATA, TATA element. (D) Transforming ability of various MLL fusion proteins. The schema depicts 
the myeloid progenitor transformation assay. RT-qPCR was performed on first- and second-round colonies. The Hoxa9 expression level normalized to 
Gapdh (representative of 2 independent experiments) is shown as the value relative to that of MLL-ENL in the second-round colonies (set at 100%). Error 
bars represent the SD of PCRs performed in triplicate. The number of CFU of each round is shown with error bars (SD from >3 independent experiments). 
Blue flag denotes the HA epitope. CXXC, CXXC domain; hMBM, high-affinity MENIN-binding motif; IBD, integrase-binding domain; LBD, ligand-binding 
domain; PWWP, PWWP domain; SET, SET domain.
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relatively weak transactivation activity (~6-fold increase). The 
GAL4–OM-LZ fusion protein (GAL4-AF10′) slightly activated 
transcription (~2-fold increase). Specific association with each 
binding platform was confirmed by fanChIP-WB (Figure 4B). 
ChIP-qPCR analysis showed that each binding platform recruit-
ed its specific binding partners to the GAL4-responsive elements 
(Figure 4C and Supplemental Figure 4A). It should be noted that 
GAL4-AF10′ induced AF4 recruitment to a small extent, sugges-
tive of a role of DOT1L as an AEP recruiter. The degree of AF4 
recruitment roughly corresponded to the degree of transactiva-
tion (Figure 4, A and C). Both DOT1L and AEP-SL1 complexes 
were recruited by GAL4-ENL′ (Figure 4C and Supplemental Fig-
ure 4B). In a condition in which DOT1L knockdown resulted in 
a decrease of HOXA9 expression (Supplemental Figure 4, C and 
D), transactivation activity of GAL4-ENL′ was not impaired (Sup-
plemental Figure 4E). These results indicate that AEP, not the 
DOT1L complex, is largely responsible for transcriptional acti-
vation, while the DOT1L complex may play a role in recruiting/
tethering AEP to the target chromatin.
We previously identified the minimum targeting module 
(MTM) necessary and sufficient for target chromatin recognition 
by MLL fusion proteins as the PWWP domain of LEDGF and the 
CXXC domain of MLL (6). To examine the functions of these bind-
ing platforms in the context of MLL fusion in hematopoietic cells, 
we generated constructs in which the 5′ portion of MLL or MTM was 
fused to each binding platform and performed a myeloid progeni-
tor transformation assay (Figure 4D and Supplemental Figure 4F). 
In this assay, functional MLL fusion proteins constitutively activate 
Hoxa9 to immortalize myeloid progenitors. The MLL-AHD (MLL-
ENL′) and MLL–OM-LZ (MLL-AF10′) fusion proteins activated 
Hoxa9 and immortalized myeloid progenitors in a manner similar 
to that seen with naturally occurring MLL fusion proteins (MLL-
ENL and MLL-AF10) in clinical cases. The MLL-CHD fusion pro-
tein (MLL–AF5-4) also activated Hoxa9 and immortalized myeloid 
progenitors, although it was the weakest in terms of clonogenicity. 
The MTM-AHD fusion protein (MTM-ENL′) successfully trans-
formed myeloid progenitors, while the MTM-CHD fusion protein 
(MTM–AF5-4) immortalized the cells at low clonogenicity, similar 
to that observed with MLL–AF5-4. Myeloid progenitors transduced 
with the MTM–OM-LZ fusion protein (MTM-AF10′) maintained a 
high level of Hoxa9 expression in the first-round colonies and pro-
gressively lost this expression and clonogenicity in later rounds, 
unlike MLL-AF10′. An artificial construct in which MTM was fused 
to full-length DOT1L (MTM-DOT1L) behaved similarly. These 
results suggest that DOT1L recruitment delays the gene silenc-
ing induced by differentiation via its transcriptional maintenance 
activity, but cannot establish a fully immortalized state.
MLL-AF10 activates transcription by providing ENL to AF4. 
Since MTM-AF10′ did not immortalize myeloid progenitors, but 
MLL-AF10′ did, we inferred that the 5′ portion of MLL contained 
additional structures necessary for full transformation by MLL-
AF10. To identify such structures, we generated a series of con-
structs in which various portions of MLL were added back to MTM-
AF10′ and examined their transforming ability (Figure 5A and 
Supplemental Figure 5A). A mutant (P′1008/1267-AF10′), which 
included the evolutionarily conserved TRX2 domain (41) (Supple-
mental Figure 5B), was able to immortalize myeloid progenitors 
(Figure 5A). Since MTM-ENL′ fully transformed myeloid progeni-
tors, we inferred that the TRX2 domain would associate with AF4. 
Indeed, fanChIP-WB analysis on a series of MLL deletion mutants 
demonstrated that MLL associated with AF4 or AF5Q31 through 
the TRX2 domain on chromatin (Figure 5B). Additionally, a region 
containing the conserved U1 small nuclear ribonucleoprotein 
(U1 snRNP) domain (Supplemental Figure 5B) also showed weak 
AF4-binding ability (Figure 5B, MLL 641/1007), which may fur-
ther contribute to AF4 recruitment. An MLL-AF10 mutant (MLL 
d869/1144-AF10′) lacking these AF4 interaction domains failed to 
fully immortalize myeloid progenitors (Figure 5A). These results 
indicate that MLL-AF10 activates its target genes through two key 
interactions: one with AF4 via the TRX2 domain and one with 
DOT1L via the OM-LZ domain.
Next, we performed loss-of-function studies for Dot1l and 
Enl using specific shRNAs on myeloid progenitors immortalized 
by MLL-ENL′, MLL-AF10′, and MLL-AF5-4. Hoxa9 expression 
in MLL-AF10′–transformed cells was substantially decreased by 
Dot1l knockdown, but not in MLL-ENL′– or MLL-AF5-4–trans-
formed cells (Figure 5C). This suggests that DOT1L is directly 
involved in MLL-AF10–dependent transcriptional activation. 
However, clonogenicity in the following round was impaired in all 
immortalized cell lines, indicating that the continuous presence 
of endogenous DOT1L is required for the long-term maintenance 
of Hoxa9 expression, as previously reported (28–31). Enl knock-
down markedly decreased Hoxa9 expression and clonogenicity 
in MLL-AF10′– and MLL-AF5-4–transformed cells, but not as 
severely in MLL-ENL′–transformed cells (Figure 5D), suggesting 
that MLL-AF10′ and MLL–AF5-4 induce AEP-SL1 complex forma-
tion on chromatin through endogenous ENL protein. Consistent 
with these notions, an MTM-DOT1L–derivative (P′1008/1267-
DOT1L) construct in which the TRX2 domain was added back to 
MTM-DOT1L, showed full transformation ability (Supplemen-
tal Figure 5, A and C–E), while its mutant proteins lacking the 
major ENL-binding motifs (P′1008/1267-DOT1L d673/1087) or 
an intact HMT domain (P′1008/1267-DOT1L mut) did not show 
this ability. These data demonstrate the importance of both the 
ENL-providing ability and the HMT activity of DOT1L in MLL-
AF10–dependent transcriptional activation.
The activities of AF4 and DOT1L cooperate in leukemogenesis. 
To investigate whether the activities of AEP and the DOT1L com-
plex functionally collaborate during leukemic transformation, we 
performed a myeloid progenitor transformation assay by simul-
taneously transducing 2 genes (Figure 6A). The clonogenicity of 
MTM–AF5-4–transduced cells was substantially increased by the 
coexpression of MTM-DOT1L. Thus, AEP-dependent transcrip-
tional activation and DOT1L-dependent transcriptional mainte-
nance collaborate to increase clonogenicity.
Next, we examined the leukemogenic potential of various 
MLL-mutant constructs in vivo (Figure 6B). Neither MTM–AF5-4 
nor MTM-AF10′ induced leukemia in vivo within 150 days, while 
MTM-ENL′ and MLL-AF10′ induced leukemia at near-full pene-
trance. These results indicate that both AEP-dependent transcrip-
tional activation and DOT1L-dependent transcriptional main-
tenance are required for the onset of leukemia in vivo. Thus, we 
conclude that the functions of both AF4 and DOT1L are required 
for MLL fusion–dependent leukemogenesis.
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Figure 5. Mechanism of MLL-AF10–dependent transformation. (A) Structural requirement of MLL-AF10 for leukemic transformation. Various MLL-AF10 
constructs were analyzed by the myeloid progenitor transformation assay, as in Figure 4D. P′, PWWP. (B) Association between MLL and AF4 on chromatin. 
293T cells transiently expressing various FLAG-tagged MLL mutants and Xpress-tagged AF4 or AF5Q31 were analyzed by fanChIP-WB using an anti-FLAG 
antibody. (C) Effect of Dot1l knockdown on various MLL fusion–transformed cells. Transduced cells were selected for puromycin resistance for 2 days. RNA 
was extracted 3 days after transduction of shRNAs. The expression levels of Dot1l and Hoxa9 normalized to Gapdh (representative of 2 independent exper-
iments) are shown as the value relative to that of the vector control (set at 100%). Error bars represent the SD of PCRs performed in triplicate. CFU relative 
to those of the vector control in the same experiment (set at 100%) is shown with error bars (SD for >3 independent experiments). *P ≤ 0.05, **P ≤ 0.01,  
§P ≤ 0.001, and #P ≤ 0.0001, by unpaired, 2-tailed t test, comparing each sample with the vector control. (D) Effect of Enl knockdown on various MLL 
fusion–transformed cells. Experiments were performed using shRNA for Enl as shown in panel C. **P ≤ 0.01, §P ≤ 0.001, and #P ≤ 0.0001, by by unpaired, 
2-tailed t test, comparing each sample with the vector control. 
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ication of the clonogenic cells. Similar results were obtained with 
MLL-AF9–, MLL-AF10–, and MLL-AF5-4–transformed cells, but 
not with E2A-HLF–transformed cells (Figure 7D). MV4-11 cells, 
which express MLL-AF4 endogenously, were also susceptible 
to the double exposure (Supplemental Figure 6, A and B). Expo-
sure of MLL-ENL cells to these 2 compounds at these suboptimal 
concentrations for only 3 days effectively decreased MLL target 
gene expression and induced the expression of Cd11b, which is a 
differentiation marker (Figure 7E). A transplantation experiment 
following the 3-day exposure ex vivo showed that the combined 
drug treatment effectively attenuated the leukemogenic potential 
in vivo (Figure 7F). Thus, therapeutics against these molecular tar-
gets that simultaneously inhibit DOT1L and MENIN may provide 
better treatment for patients than do single drugs.
Discussion
We showed that MLL fusion proteins, such as MLL-ENL and MLL-
AF10, exert 2 separate actions to cause leukemia in vivo: AEP- 
dependent transcriptional activation and DOT1L-dependent tran-
scriptional maintenance. Although PRC1 can be recruited to some 
MLL-ENL target loci, MLL fusion proteins appear to function pri-
marily in the absence of PRC1.
ENL binds specifically to chromatin containing H3K9/18/27ac 
via the YEATS domain (17). Localization of ENL is also closely 
correlated with the presence of the DOT1L-AF10 family complex 
(Figure 1, E and F), which associates with chromatin containing 
unmodified H3K27 (39). Given observations, we propose the fol-
lowing model (Figure 8A): (a) ENL forms a metastable complex 
with the DOT1L-AF10 family complex on chromatin containing 
unmodified H3K27; (b) upon acetylation of nearby nucleosomes, 
the ENL-containing DOT1L complex binds to H3K9/18/27ac 
marks via the YEATS domain; (c) this complex presents ENL to 
AF4 proteins to form AEP on the chromatin; and (d) the chroma-
tin-bound AEP further recruits SL1 to initiate transcription, while 
the DOT1L-AF10 family complex inhibits SIRT1-dependent tran-
scriptional repression by methylating lysine 79 on histone H3 of 
the nearby chromatin. Since AHD binds to AF4 proteins with a 
higher affinity than it does to DOT1L and has an intrinsically dis-
ordered structure that facilitates the exchange of interacting part-
ners (36), MLL-ENL primarily associates with AEP components 
on chromatin (Figure 8B).
The mechanism by which MLL-AF10 activates gene expres-
sion and transforms hematopoietic progenitors was previously 
unclear and controversial (11, 26). The results from this study 
show that simple recruitment of DOT1L to target promoters only 
prolongs the expression of target genes for a limited period (Fig-
ure 4D). We discovered that the TRX2 domain of MLL, which 
recruits AF4, is additionally required for MLL-AF10–dependent 
transformation (Figure 5, A and B). The results of a structural and 
functional analysis of artificial MLL-DOT1L fusion proteins indi-
cated that DOT1L exerts its transforming potential through its 
ENL-binding motifs (Supplemental Figure 5, C–E). These results 
suggest that the MLL-AF10–DOT1L complex functions both as an 
ENL provider for AF4 to efficiently load AEP onto chromatin and 
as a chromatin modifier. Thus, we propose a model in which MLL-
AF10 recruits ENL through DOT1L and then provides it to AF4 to 
induce AEP-SL1 complex formation (Figure 8C).
Simultaneous inhibition of MENIN and DOT1L efficiently erad-
icates MLL cells. Because AF4 recruitment appears to be primar-
ily dependent on MLL-ENL (Figure 3) and target recognition by 
MLL fusion proteins requires MENIN (4, 5), we hypothesized that 
MI-2-2, a MENIN-MLL interaction inhibitor (42), would inhibit 
AF4 recruitment to the MLL target chromatin in MLL-AEP leu-
kemia cells. Indeed, MI-2-2 impaired the expression of HOXA9 
and MEIS1 in NODAL modulator 1 (NOMO-1) cells, which express 
MLL-AF9 endogenously (Figure 7, A and B). There was no effect 
on the expression of either gene by a near-complete knockdown 
of WT MLL, indicating that the effects of MI-2-2 could be most-
ly attributed to the disruption of the MLL-AF9–MENIN com-
plex. Given the collaborative effects of AEP and DOT1L on MLL 
fusion–dependent gene activation, we hypothesized that the com-
binatorial use of a MENIN inhibitor and a DOT1L inhibitor might 
have synergistic effects on leukemic cell growth. MI-2-2 and EPZ-
5676, a DOT1L HMT inhibitor (34), each reduced clonogenicity 
by approximately 30% to 40% at 3 μM in leukemia cells induced 
by MLL-ENL in vivo (Figure 7C). The colony-forming ability 
of these leukemia cells ex vivo represents the frequency of self- 
renewing leukemia-initiating cells (3, 43). Concomitant exposure 
to both compounds at this concentration resulted in efficient erad-
Figure 6. Recruitment of both AF4 and DOT1L activities is required for 
MLL fusion–dependent leukemogenesis. (A) Cooperative transformation 
by recruitment of AF4 and DOT1L activities. Doubly transduced cells were 
selected in the first round. Hoxa9 expression and colony-forming activity 
were analyzed as in Figure 4D. **P ≤ 0.01, by ordinary 1-way ANOVA, 
comparing the indicated sample pairs. neo, neomycin. (B) Leukemogenic 
potential of various constructs in vivo. Survival of mice transplanted with 
hematopoietic progenitors transduced with the indicated transgenes.  
n values indicate the number of mice analyzed.
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Figure 7. Combined antileukemic effects of the MENIN-MLL interaction inhibitor and the DOT1L HMT inhibitor. (A) Knockdown of WT MLL in NOMO-1 
cells. NOMO-1 cells transduced with shRNA for WT MLL were analyzed by WB. MLLN, the amino-terminal MLL fragment; MLLC, the carboxyl-terminal MLL 
fragment. (B) Effect of MI-2-2 in NOMO-1 cells. NOMO-1 cells in A were cultured in the presence of MI-2-2 (10 μM) for 1 day and analyzed by RT-qPCR. The 
expression level, normalized to ACTB (representative of 2 independent experiments), is shown as the value relative to that of the vector/vehicle control 
(set at 100%). Error bars represent the SD of PCRs performed in triplicate. **P ≤ 0.01 and #P ≤ 0.0001, by ordinary 1-way ANOVA, comparing each sample 
with the vector/vehicle control. (C) Combined effects of MI-2-2 and EPZ-5676 on MLL-ENL leukemia cells. Murine MLL-ENL leukemia cells were cultured in 
the presence of the drugs at the indicated concentrations ex vivo. CFU relative to those of the vehicle control (set at 100%) are shown with error bars (SD 
of >3 independent experiments). *P ≤ 0.05, **P ≤ 0.01, §P ≤ 0.001, and #P ≤ 0.0001, by ordinary 1-way ANOVA, comparing each sample with the vehicle 
control. Images of colonies on day 6 are shown. Scale bars: 100 μm. (D) Combined effects of MI-2-2 and EPZ-5676 on various immortalized progenitors. 
Murine myeloid progenitors immortalized by various transgenes were analyzed, as in C. **P ≤ 0.01 and #P ≤ 0.0001, by ordinary 1-way ANOVA, comparing 
each sample with the vehicle control. (E) Gene expression after exposure to MI-2-2 and/or EPZ-5676. RT-qPCR analysis was performed on MLL-ENL leuke-
mia cells after 3 days of drug treatment. The expression level normalized to Gapdh (representative of 2 independent experiments) is shown as the value 
relative to that of the vehicle control (set at 100%). Error bars represent the SD of PCRs performed in triplicate. **P ≤ 0.01 and #P ≤ 0.0001, by ordinary 
1-way ANOVA, comparing each sample with the vehicle control. (F) Combined effects of MI-2-2 and EPZ-5676 on the leukemia stem cell potential. MLL-
ENL leukemia cells treated with the drugs for 3 days were transplanted into sublethally irradiated syngeneic mice. *P ≤ 0.05 and **P ≤ 0.01, by log-rank 
test for the indicated pairs.
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H2B lysine 120 (H2BK120) stim-
ulates DOT1L-dependent H3K79 
methylation (44). Consistent with 
this hypothesis, RNF20, an 
H2BK120 ubiquitin ligase, has 
been shown to play important 
roles in the continuous growth 
of MLL-AF9 leukemia cells (45). 
MLL-AF4 leukemia cells contain 
MLL target chromatin enriched 
with H3K79me2 and depend on 
DOT1L for their proliferation (46), 
indicating that the endogenous 
DOT1L complex plays a signif-
icant role in leukemic transfor-
mation by MLL-AF4 (Figure 8D).
The requirement of AF4-bind-
ing platforms for MLL fusion–
dependent transformation (20) 
indicates that the AF4 activity 
is recruited by the MLL fusion–
MENIN complex, while the DOT1L 
activity appears to be recruited to 
the MLL target loci either direct-
ly or indirectly (11, 25, 28–30, 32, 
46, 47). These 2 activities cooper-
atively increase clonogenicity in 
MLL cells (Figure 6). Simultane-
ous exposure to the MENIN-MLL 
interaction inhibitor (42) and the 
DOT1L HMT inhibitor (34), which 
would induce dissociation of the 
MLL fusion–MENIN–AF4 complex 
from target chromatin and loss of 
the DOT1L HMT activity, eradi-
cated the leukemia-initiating cells 
more efficiently than did the use of 
a single drug (Figure 7F), providing 
a rationale for the simultaneous 
administration of these 2 drugs to 
improve treatment efficacy. Our 
results suggest that WT MLL may 
mediate AEP recruitment via its 
TRX2 domain in non–MLL-r condi-
tions. NPM1 mutation–associated 
leukemia, in which WT MLL activates HOXA9 and MEIS1, is also 
susceptible to the combinatorial use of the MENIN-MLL interaction 
inhibitor and the DOT1L HMT inhibitor (48), suggesting that the 
MLL/AEP axis and DOT1L activity also cooperate in nucleophos-
min (NPM1) mutation–associated leukemia. Because of the cooper-
ative nature of transcriptional activation and maintenance, the com-
binatorial use of 2 reagents that inhibit these 2 axes may improve the 
clinical outcome compared with the use of a single reagent.
Methods
Vector construction. The pMSCV-neo-MLL-ENL, MLL-AF10, and E2A-
HLF vectors and their derivatives have been previously described (6). 
The artificial construct in which MTM was fused with the 
AF4-binding platform (MTM–AF5-4) activated MLL target genes 
and transformed myeloid progenitors ex vivo (Figure 4D), but failed 
to cause leukemia in vivo (Figure 6B). In contrast, MTM-ENL′, which 
could facilitate both AF4-dependent transcriptional activation and 
DOT1L-dependent transcriptional maintenance, efficiently induced 
leukemia, indicating that both activation and maintenance of the 
MLL target genes are required for the onset of leukemia in vivo. These 
2 activities likely feed off each other, as the DOT1L-dependent tran-
scriptional maintenance activity protects H3K9/18/27ac from SIRT1 
(24) to set the stage for subsequent AEP-SL1 complex formation 
(Figure 8A), while transcription-coupled ubiquitination of histone 
Figure 8. Working models of gene activation. Working models of gene activation by AEP (A), MLL-ENL (B), MLL-
AF10 (C), and MLL-AF4/5Q31 (D). Me, methylated.
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pyrophosphate, 5 mM EDTA, 10 mM NaF, 0.1% NP-40, 10% glycer-
ol, 1 mM DTT, and EDTA-free protease inhibitor cocktail) was then 
added to increase the solubility. The chromatin fraction was cleared 
by centrifugation and subjected to IP with specific antibodies (Sup-
plemental Table 1) and magnetic microbeads (Protein G Magnetic 
Beads; Invitrogen, Thermo Fisher Scientific) or with anti-FLAG M2 
antibody–conjugated beads. The precipitates were washed 5 times 
with washing buffer (1:1 mixture of lysis buffer and MNase buffer with 
20 mM EDTA) and then eluted in elution buffer. The eluted material 
was analyzed by various methods including Western blotting, qPCR, 
and deep sequencing. The fanChIP-WB analysis was performed using 
293T-derivative cell lines.
Western blotting. Western blotting was performed as previously 
described (51). The antibodies used in this study are listed in Sup-
plemental Table 1.
Fractionation-assisted cross-linked ChIP. For fractionation-assisted 
cross-linked ChIP (faxChIP), cells were cross-linked by a 5-minute incu-
bation with 5% formaldehyde. Glycine was added to stop the cross-link-
ing reaction at a final concentration of 125 mM. After rinsing with PBS, 
cells were suspended in CSK buffer and centrifuged to remove the solu-
ble fraction in the same manner as for the fanChIP protocol. The pellet 
was resuspended in MNase buffer and treated with MNase at 37°C for 
3 to 6 minutes to obtain oligonucleosomes. The MNase reaction was 
stopped by adding EDTA (pH 8.0) at a final concentration of 20 mM. 
The chromatin was solubilized by adding SDS at a final concentration 
of 1% and incubated on ice for 10 minutes. The chromatin fraction was 
cleared by centrifugation and mixed with 2 volumes of IP dilution buffer 
(0.01% SDS, 1.1% Triton-X-100, 1.2 mM EDTA, pH 8.0, 16.7 mM Tris-
HCl, pH 7.6, 167 mM NaCl, and EDTA-free protease inhibitor cocktail) 
and subjected to IP, as in the fanChIP protocol. faxChIP was applied for 
the ChIP analysis of H3K79me2 and H3K27me3.
ChIP-qPCR and ChIP-seq. The eluted material obtained by fan-
ChIP (or faxChIP) was extracted by phenol/chloroform/isoamyl 
alcohol. DNA was precipitated with glycogen (Nacalai Tesque) and 
analyzed by qPCR and deep sequencing. Deep sequencing of the pre-
cipitated DNA was performed using a TruSeq ChIP Sample Prep Kit 
(Illumina) and a Genome Analyzer IIx (Illumina) or a HiSeq 2000 
(Illumina) at the core facility of Hiroshima University (Hiroshima, 
Japan). The data were visualized using the Integrative Genome View-
er (The Broad Institute). qPCR analysis of the precipitated DNA was 
performed using the custom-made primer sets listed in Supplemental 
Table 2. The value relative to the input was determined using a stan-
dard curve and the relative quantification method.
Virus production. The ecotropic retrovirus was produced using 
PLAT-E packaging cells (50). The lentivirus was produced in 293TN 
cells using the pMDLg-pRRE, pRSV-rev, and pMD2.G vectors (52). 
The supernatant medium containing the virus was harvested 24–48 
hours following transfection and used in viral transduction.
Myeloid progenitor transformation assay. The myeloid progenitor 
transformation assay was performed as previously described (6). Bone 
marrow cells were harvested from the femurs and tibiae of 5-week-
old female C57BL/6 mice (purchased from CLEA Japan Inc.). c-Kit–
positive cells were enriched using magnetic beads conjugated with 
an anti–c-Kit antibody (Miltenyi Biotec), transduced with a recombi-
nant retrovirus by spinoculation, and then plated on a methylcellulose 
medium (IMDM containing 20% FBS, 1.6% methylcellulose, and 100 
μM β-mercaptoethanol) containing murine stem cell factors, IL-3, and 
Various new gene constructs were generated by restriction enzyme 
digestion/PCR–based mutagenesis. The cDNAs were cloned into the 
pMSCV neo vector (for virus production) (Clontech) or into the pCMV5 
vector and the pcDNA4 HisMax vector (for transient expression). 
The pLKO-zeo-TK-RL reporter and the pLKO-puro-FR-LUC (or bla-
FR-LUC) reporter vectors have been previously described (20). The 
shRNA expression vectors, targeting murine Enl (TRCN0000084405); 
Taf1c (TRCN0000082215); Dot1l no. 1 (TRCN00000125101); Dot1l 
no. 2 (TRCN0000125099); human DOT1L (TRCN0000020212); 
MLL (TRCN0000234743); ENL no. 1 (TRCN0000019291; ENL 
no. 2 (TRCN0000019293); and TAF1D (TRCN0000134377), were 
obtained from GE Healthcare.
Cells and cell culture. The human leukemia cell lines K562 (JCRB 
Cell Bank), HB1119 (40, 49), and NOMO-1 (JCRB Cell Bank) were cul-
tured in RPMI 1640 medium supplemented with 10% FBS and pen-
icillin-streptomycin (PS). The MV4-11 (ATCC) cell line was cultured 
in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 
10% FBS and PS. The 293T and 293TN (System Biosciences) cell lines 
and iMEFs (20) were cultured in DMEM supplemented with 10% FBS 
and PS. Ecotropic virus–packaging cells (PLAT-E cells, a gift of Toshio 
Kitamura, The University of Tokyo, Tokyo, Japan) (50) were cultured 
in DMEM supplemented with 10% FBS, puromycin, blasticidin, and 
PS. 293TL cells, which carry the GAL4-responsive luciferase reporter, 
were generated by transduction of the pLKO-puro-FR-LUC report-
er (20). 293TL cells stably expressing various FLAG-tagged GAL4 
(fGAL4) fusion proteins were generated by sequential transduction of 
the pLKO-zeo-TK-RL reporter, the pLKO-bla-FR-LUC reporter, and 
the pMSCV-hygro-fGAL4 fusion vectors.
nucfrIP. Subcellular fractions of 293T cells were obtained by cyto-
skeleton (CSK) buffer extraction and micrococcal nuclease (MNase) 
treatment as previously described (6). 293T cells cultured in a 10-cm 
dish were resuspended in 1 ml CSK buffer (100 mM NaCl, 10 mM 
PIPES, pH 6.8, 3 mM MgCl2, 1 mM EGTA, pH 7.6, 0.3 M sucrose, 0.5% 
Triton X-100, 5 mM sodium butyrate, 0.5 mM DTT, and EDTA-free 
protease inhibitor cocktail [Roche]), incubated on ice for 5 minutes, 
and then centrifuged (400 ×g, 4°C, 4 min). The supernatant was 
removed, and the pellet was resuspended in 1 m MNase buffer (50 mM 
Tris-HCl, pH 7.5, 4 mM MgCl2, 1 mM CaCl2, 0.3 M sucrose, 5 mM sodi-
um butyrate, 0.5 mM DTT, and protease inhibitor cocktail). One unit 
of MNase (Sigma-Aldrich) was added to the suspension, and the mix-
ture was incubated at 37°C for 10 to 12 minutes to obtain mononucle-
osomes. The MNase reaction was stopped by adding EDTA (pH 8.0) 
at a final concentration of 20 mM. The reaction mixture was centri-
fuged (17,000 ×g, 4°C, 5 min) to separate the supernatant (nucleosome 
fraction) and the pellet. The nucleosome fractions were subjected to 
IP using specific antibodies (Supplemental Table 1), washed 5 times 
with MNase buffer containing 20 mM EDTA, and then eluted in elu-
tion buffer (1% SDS and 50 mM NaHCO3). The eluted material was 
analyzed by Western blotting and MS.
fanChIP. The chromatin fractions of 293T derivatives and HB1119 
cells were prepared as previously described (6). Cells were suspend-
ed in CSK buffer and centrifuged to remove the soluble fraction in the 
same manner as for the nucfrIP analysis. The pellet was resuspended 
in MNase buffer and treated with MNase at 37°C for 3 to 6 minutes 
to obtain oligonucleosomes. The MNase reaction was stopped by 
adding EDTA (pH 8.0) at a final concentration of 20 mM. Lysis buf-
fer (250 mM NaCl, 20 mM sodium phosphate, pH 7.0, 30 mM sodium 
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full MS and MS/MS, respectively. For fragmentation, electron transfer 
dissociation (ETD) was used.
RT-qPCR. RNA was prepared using the RNeasy Kit (QIAGEN) and 
reverse transcribed using a Superscript III First Strand cDNA Synthe-
sis Kit with oligo(dT) primers (Life Technologies, Thermo Fisher Sci-
entific). Gene expression was confirmed by qPCR using the TaqMan 
probes described in Supplemental Table 3 (Life Technologies, Ther-
mo Fisher Scientific). The expression levels, normalized to those of 
Gapdh, Actb, or Tbp for mouse transcripts and ACTB or TBP for human 
transcripts, were determined using a standard curve and the relative 
quantification method as described in ABI User Bulletin no. 2.
Cell viability assay. Five thousand MV4-11 cells were cultured in 
96-well plates with MI2-2 and/or EPZ-5676 in IMDM containing 10% 
FBS and PS for 5 days. After incubation, cell survival was measured with 
the PrestoBlue Cell Viability Reagent (Thermo Fisher Scientific). The 
drugs were dissolved in DMSO to a final DMSO concentration of 0.2%.
Accession numbers. The deep-sequencing data from the RNA-seq 
and ChIP-seq analyses have been deposited in the DNA Data Bank 
of Japan (DDBJ) Sequence Read Archive under accession numbers 
DRA004871 through DRA004875.
Statistics. Statistical significance was calculated by unpaired, 
2-tailed t test (for comparisons between 2 samples); ordinary 1-way 
ANOVA (for ungrouped multiple comparisons); or log-rank test (for 
survival curves) using GraphPad Prism 6.0 (GraphPad Software). 
P values of greater than 0.05 were considered nonsignificant.
Study approval. All experiments involving animals were approved 
by the IACUC of Kyoto University.
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granulocyte-macrophage CSF (10 ng/ml of each), G418 (1 mg/ml), 
and/or puromycin (2 μg/ml), which were added to the first round of 
culture to select for transduced cells. Hoxa9 was quantified by reverse 
transcription-qPCR after the first round of culture. CFU were quanti-
fied per 104 plated cells after 4 to 6 days in culture.
In vivo leukemogenesis assay. c-Kit–positive cells (2 × 105) prepared 
from mouse femurs and tibiae were transduced with retrovirus by spi-
noculation and intravenously transplanted into sublethally irradiated 
(6 Gy) C57BL/6 mice. Moribund mice were euthanized, and the iso-
lated cells were cultured for more than 3 passages in the methylcellu-
lose medium used for the myeloid progenitor transformation assay to 
remove untransformed cells and then subjected to secondary trans-
plantation. Leukemia cells (2 × 105) cultured ex vivo, with or without 
the exposure to drugs, were transplanted in the same manner as for 
the primary transplantation. 
Transactivation assay. The expression vectors for the various 
GAL4 fusion proteins were transfected in 293TL cells along with pRL-
tk plasmid (Promega). Luciferase/Renilla luciferase activity was mea-
sured using the Dual-Luciferase Reporter Assay System (Promega). 
Luciferase activity values were normalized to Renilla luciferase activi-
ty and expressed as the mean and SD of triplicate samples.
RNA-seq. Total RNA was prepared using the RNeasy Kit (QIA-
GEN) and the quality assessed using a eukaryote Bioanalyzer RNA 
Nano Kit (Agilent Technologies). Deep sequencing of total RNA was 
performed using a SureSelect Strand Specific RNA Library Prep Kit 
(Agilent Technologies) and a Genome Analyzer IIx (Illumina) at the 
core facility of Hiroshima University. Gene expression was normalized 
as reads per kilobase of exon per million mapped (RPKM), with the 
cutoff value set to 5 in the vector control. Gene set enrichment analysis 
(GSEA) was carried out using the preranked method, with 1,000 per-
mutations with the gene sets.
Liquid chromatography–tandem MS analysis. Trypsin digestion of 
proteins was performed as previously described (6). Tandem MS (MS/
MS) analysis was performed using an LTQ Orbitrap ELITE ETD mass 
spectrometer (Thermo Fisher Scientific). The methods used for liquid 
chromatography–MS/MS (LC-MS/MS) were slightly modified from 
those described previously (53). The mass spectrometer was operated 
in data-dependent acquisition mode, in which MS acquisition with a 
mass range of 400 to 1,000 m/z was automatically switched to MS/
MS acquisition under the control of Xcalibur software (Thermo Fisher 
Scientific). The top 4 precursor ions in the MS scan were selected by 
Orbitrap, with a resolution of R = 240,000, and the ions in subsequent 
MS/MS scans were analyzed with an ion trap in automated gain con-
trol (AGC) mode, in which AGC values were 1 × 106 and 1.00 × 104 for 
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